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Abstract
Expression of the EVI1 proto-oncogene is deregulated by chromosomal translocations in some 
cases of acute myeloid leukemia (AML) and is associated with poor clinical outcome. Here, 
through transcriptomic and metabolomic profiling of hematopoietic cells, we reveal that EVI1 
overexpression alters cellular metabolism. A pooled shRNA screen identified the ATP-buffering, 
mitochondrial creatine kinase CKMT1 as a metabolic dependency in EVI1-positive AML. EVI1 
promotes CKMT1 expression by repressing the myeloid differentiation regulator RUNX1. 
Suppression of arginine-creatine metabolism by CKMT1-directed shRNAs or by the small 
molecule cyclocreatine selectively decreased the viability, promoted cell cycle arrest and apoptosis 
of human EVI1-positive AML cells, and prolonged survival in human orthotopic and mouse 
primary AML models. CKMT1 inhibition alters mitochondrial respiration and ATP production, an 
effect that is abrogated by phospho-creatine-mediated reactivation of the arginine-creatine 
pathway. Targeting CKMT1 is a promising therapeutic strategy for this EVI1-driven AML subtype 
that is highly resistant to current treatment regimens.
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INTRODUCTION
Recent investigations into the relationship between cancer and cellular metabolism have 
revealed the strong dependency of different cancers on a diverse array of metabolic 
pathways. Therefore, identifying mechanisms by which these metabolic pathways become 
deregulated in the first place en route to, or as a result of, the development of cancer has 
emerged as a major area of therapeutic and biological interest.
Deregulation of metabolic pathways can occur through multiple mechanisms, including 
alterations in the cellular landscape brought about by mutations in metabolic enzymes (e.g., 
IDH1/IDH2 and SDH)1–4. IDH1 and IDH2 mutations, which are initiating events in high-
grade gliomas and frequently occur in acute myeloid leukemia (AML), interfere with normal 
IDH1/2 function to produce the pro-oncogenic metabolite R(−)-2-hydroxyglutarate which 
acts as an epigenetic modulator5–8. Deregulation of metabolic pathways can also occur 
through aberrant expression of transcription factors, such as the proto-oncogene MYC. 
Transcriptional changes resulting from aberrantly activated MYC increase glucose uptake 
and glycolysis in cancer cells and stimulate glutaminolysis, serine/glycine metabolism, and 
lipid biosynthesis9. Although MYC and other transcription factors are typically considered 
pharmacologically challenging targets, the diverse metabolic alterations induced by these 
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transcription factors may constitute another source of unique cancer dependencies and 
provide multiple downstream opportunities for therapeutic intervention. It is thus necessary 
not only to identify the metabolic changes which occur with cancer development, but to link 
these programs to initiating events and oncogenic drivers; the latter will enable identification 
of patient populations that may benefit from specific metabolic interventions.
Transcriptional modulators are deregulated in AML either by translocation (e.g., MLL-AF9, 
AML1-ETO, or PML-RARA) or aberrant expression, as is true of EVI110,11. Abnormal 
expression of this transcription factor through chromosome 3q26 rearrangements (e.g., t(3;3)
(q21;q26) or inv3(q21;q26)) promotes the development or progression of high-risk acute 
myeloid leukemia (AML), for which current treatment regimens remain inadequate12–15. 
Here we integrate genomic and metabolic screening to identify a new druggable metabolic 
dependency in mouse and human EVI1-positive AML, including cell lines and primary 
patient samples.
RESULTS
EVI1 modulates metabolism in AML cells
To characterize the transcriptional consequences of EVI1 overexpression in AML, we 
generated an EVI1-dependent gene signature from murine bone marrow LinLow cells 
infected with a retroviral construct encoding Evi1 (GSE 3472916). We then used this 
signature to conduct an open-ended enrichment analysis of 4725 curated gene sets from the 
c2 collection assembled from various sources such as online pathway databases, publications 
in PubMed, and knowledge of domain experts available from MSigDB (Figure 1A). We 
confirmed the findings of other investigators that gene sets related to cell proliferation and 
differentiation were enriched in genes whose expression is suppressed by enforced Evi1 
overexpression16–18. Multiple cell metabolism-related gene sets were also significantly 
enriched in an unbiased search of the complete c2 collection. Evi1 overexpression 
modulated genes from cellular energy-related pathways, including glycolysis, the TCA 
cycle, and oxidative phosphorylation, purine and pyrimidine synthesis, and the metabolism 
of various amino acids.(Figure 1B). Using an unbiased metabolomic profiling approach, we 
established that of 292 small metabolites detected by mass spectrometry, steady state levels 
of 82 were significantly (−log10 (p value) ≤ 1) changed by Evi1-expression (Supplementary 
Figure S1). The most highly enriched metabolic pathways were related to purine and 
pyrimidine metabolism, amino acid metabolism (alanine, aspartate, glutamate, arginine, and 
proline), the pentose phosphate pathway and glycolysis (Figure 1C).
To assess whether upregulation of EVI1 in human AML cell lines might promote oncogenic 
dependency on metabolic enzymes, we performed an shRNA screen against 67 genes 
encoding enzymes from glycolysis, the pentose phosphate pathway, the TCA cycle, and 
related metabolic pathways in the AML cell lines TF-1 and UCSD-AML1, both of which 
express EVI1. These cells were infected with the shRNA library and expanded until day 36 
at which point genomic DNA was harvested and hairpin representation assessed by 
sequencing and compared to the representation of the input genomic DNA at day 0. We 
identified hairpin sequence that was depleted (hairpins target leukemia-promoting genes) or 
enriched (hairpins targeting leukemia-suppressing genes) at 36 days compared to the input 
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genomic DNA. These experiments identified 9 depleted and 6 enriched genes overlapping in 
both lines, tested with at least two hairpins (Figure 1D and Supplementary Table S1). As 
expected, three positive control tumor suppressor genes, PTEN, TP53 and RB1, scored 
among the top enriched hits. Three genes of interest – Ckmt1, Cs, and Sdha genes (murine 
homologs of human CKMT1, Citrate Synthase (CS) and Succinate Dehydrogenase 
Complex, Subunit A (SDHA), respectively) – were both upregulated by genomic profiling in 
Evi1-transduced cells and depleted by multiple shRNAs in the TF-1 and UCSD-AML1 
AML cell lines (Figure 1E). We then infected TF-1 AML cells with multiple hairpins that 
markedly reduced CKMT1, SDHA, and CS protein levels (Figure 1F, right panel). While all 
hairpins significantly decreased cell growth over a 12-day time course, CKMT1 depletion 
caused the most pronounced growth inhibition (Figure 1F).
CKMT1 is a target in EVI1-positive leukemia
To address the potential relationship between EVI1 expression and dependence on CKMT1, 
we expanded our investigation to a larger panel of human AML cell lines with and without 
elevated EVI1 expression. All four EVI1-expressing AML cell lines exhibited elevated 
CKMT1 protein expression and activity (Figure 2A and 2B). The viability of these four cell 
lines was more strongly decreased compared to all the other lines tested in response to a 
treatment with cyclocreatine, an analog of the CKMT1 substrate creatine and inhibitor of the 
creatine biosynthesis pathway (Figure 2C). Furthermore, three AML cell lines with elevated 
EVI1 expression – UT-7, TF-1, and UCSD-AML1 – exhibited enhanced sensitivity to a 
reduction in CKMT1 expression mediated by doxycycline-inducible shRNAs in comparison 
with the other cell lines tested (Figure 2D). The human Kasumi-3 cell line was not tested in 
this experiment due to its poor transduction efficiency. Similar growth defects were observed 
with non-inducible CKMT1-targeting shRNAs (Supplementary Figure S2A and S2B). These 
AML cell lines are grown in GM-CSF, and withdrawal of GM-CSF neither affected CKMT1 
expression nor sensitivity of EVI1-expressing cells to cyclocreatine (Supplementary Figures 
S2C and S2D). Conversely, GM-CSF supplementation did not promote CKMT1 expression 
in the two AML cell lines tested to represent EVI1-null, CKMT1-null cells: HL-60 and 
U937 (Supplementary Figures S2E).
Finally, we assayed EVI1 expression by flow cytometry in a panel of 68 unselected primary 
AML patient specimens (Figure 2E and Supplementary Table S2). Samples with at least 
5×106 blast cells were subsequently analyzed by flow cytometry and immunoblot. The four 
leukemias with the highest levels of EVI1 expression showed higher CKMT1 protein levels 
and enhanced sensitivity to cyclocreatine treatment compared to the leukemias with low 
EVI1 expression (Figures 2E–2G). Together, these studies indicate that elevated CKMT1 
expression and biochemical dependence on this metabolic pathway are correlated with high 
levels of EVI1 expression in both human AML cell lines and primary patient specimens.
EVI1 promotes CKMT1 expression through RUNX1 repression
To clarify how EVI1 regulates cellular CKMT1 expression, we first infected mouse Linlow, 
c-kit+ bone marrow cells with either an empty MSCV vector or with a construct encoding 
EVI1. Consistent with our analysis of human AMLs, enforced Evi1 expression increased 
Ckmt1 protein and mRNA levels (Figures 3A and 3B). Moreover, doxycycline induction of 
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three independent shRNA molecules targeting EVI1 reduced CKMT1 expression in TF-1 
and UCSD-AML1 cells (Figure 3C). Then, we used a luciferase reporter system in which 
the CKMT1 gene promoter was cloned upstream of a luciferase cassette, and levels of 
CKMT1 transactivation were assessed using bioluminescence (Figure 3D). Co-expression of 
EVI1 and the CKMT1-Luc promoter in HEK293E cells activated CKMT1 transcription. 
Deleting a promoter region between −1169 and −943 bp upstream of the transcriptional start 
site increased basal CKMT1 transactivation at a similar fold-increase to that observed upon 
EVI1 overexpression. This effect was recapitulated by deletion of a RUNX1 consensus 
binding motif ACCACA (ΔACCACA) from the −1169/−943 CKMT1 promoter sequence 
(Figure 3E), suggesting that RUNX1 might repress CKMT1 expression through direct 
binding to its promoter. In accordance with this idea, RUNX1 overexpression impeded the 
capacity of EVI1 to transactivate CKMT1 (Figure 3F). EVI1 knockdown promoted both an 
increase in RUNX1 and a decrease in CKMT1 expression. Furthermore, RUNX1-directed 
shRNAs, which abrogated RUNX1 upregulation, prevented a decrease of CKMT1 
expression upon EVI1 knockdown (Figure 3G).
We then used a ChIP-qPCR approach to dissect the sequential events involved in EVI1-
induced CKMT1 upregulation and the possible role of RUNX1 as an intermediate in this 
process (Figure 3H–3L). Multiple red peaks corresponding to EVI1-binding regions 
appeared on both murine and human RUNX1 gene tracks from two ChIP-sequencing 
experiments19,20 (Figure 3H). After immunoprecipitation of Evi1 from Evi1-overexpressing 
primary bone marrow murine cells and Runx1 promoter amplification by qPCR, we found a 
significant increase in Evi1 binding at the Runx1 promoter, accompanied by an increased 
amount of histone repressive mark H3K27Me3 at the same promoter region (Figure 3I). This 
was associated with a decrease in the expression of RUNX1 mRNA and protein levels 
(Supplementary Figure S3A and S3B). At basal conditions, Runx1 is bound to Ckmt1 
promoter in normal bone marrow cells. Evi1 overexpression, however, decreased Runx1 
binding to the Ckmt1 promoter, as well as the amount of bound repressive mark H3K27me3, 
and increased the binding signal of the transcriptional activation histone mark H3K27Ac 
(Figure 3J). This was associated with increased expression of Ckmt1 mRNA and protein 
levels (Supplementary Figures S3A and S3B). In contrast, EVI1 knockdown in UCSD-
AML1 cells enhanced RUNX1 expression and binding at the CKMT1 promoter (Figure 3K, 
and Supplementary Figure S3C and 3D). This led to an increased H3K27Me3 binding signal 
and a reduced amount of bound H3K27Ac at the CKMT1 promoter and was associated with 
a decreased expression of CKMT1 (Figure 3K). In contrast, concomitant EVI1 and RUNX1 
knockdown decreased repressive H3K27Me3 histone mark level at the CKMT1 promoter 
(Figure 3L). Taken together, these results show that EVI1 represses RUNX1 expression by 
direct binding to its promoter. This, in turn, eliminates repressive RUNX1 binding at the 
CKMT1 promoter and thereby promotes CKMT1 expression. Moreover, we also observed 
that RUNX1-directed shRNAs attenuated by 17-fold (based on the average bioluminescence 
across the two hairpins) the reduced disease burden caused by EVI1 depletion (Figure 3M). 
Finally, we explored the relationship between EVI1 and RUNX1 expression with CKMT1 
mRNA levels in two AML transcriptional datasets (GSE14468 and GSE10358). We divided 
these cohorts into four subgroups: EVI1high/RUNX1low, EVI1high/RUNX1high, EVI1low/
RUNX1low, and EVI1low/RUNX1high. Consistent with our mechanistic analysis, AML 
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samples with high CKMT1 levels were significantly more represented within the EVI1high/
RUNX1low subgroup than in the three other subgroups (Figure 3N).
Creatine kinase activity drives mitochondrial function and ATP production
CKMT1 promotes the metabolism of arginine to creatinine. To determine the effect of 
CKMT1 suppression on this pathway, we measured the metabolic flux of stable-isotope 
labeled L-arginine 13C6 through creatine synthesis, ornithine / spermine and ornithine / urea 
cycle, and the glutamate pathway using mass spectrometry (Figure 4A). As expected, both 
CKMT1 knockdown and cyclocreatine treatment in UCSD-AML1 and TF-1 cells 
diminished incorporation of L-Arginine 13C6 into creatinine. Creatinine is the end 
metabolite product of the creatine synthesis pathway and is spontaneously synthesized from 
phospho-creatine (Figure 4A–C and Supplementary Figure S4A). We also observed a 
significant decrease in arginine 13C6 incorporation into the precursor metabolite of the 
creatine synthesis pathway, guanidinoacetate, suggesting an inhibitory feedback loop of end 
metabolite products on the guanidinoacetate-producing enzyme glycine amidinotransferase, 
GATM. Of note, cyclocreatine treatment had a broader effect than shRNA-mediated 
CKMT1 depletion on arginine metabolism because it also impaired production of glutamate, 
α-ketoglutarate, and L-arginino-succinate (Figure 4C). Co-treatment of cells with exogenous 
phospho-creatine activated production of guanidinoacetate 13C and creatinine 13C from 
arginine 13C6 and thereby rescued cyclocreatine-induced defects on the creatine synthesis 
pathway alone, without affecting production of glutamate, α-ketoglutarate, and L-arginino-
succinate (Figure 4C and Supplementary Figure S4B). Activation of the arginine-creatine 
pathway by phospho-creatine prevented the loss of viability of human EVI1-positive AML 
cells induced by cyclocreatine or CKMT1-directed shRNAs, and also maintained the serial 
replating activity of Evi1-transformed bone marrow cells (Figure 4D–4F).
We next used a metabolism profiling approach to characterize the effect of CK pathway 
alteration on global cell metabolism. Steady state levels of 48 metabolites highly enriched in 
pathways related to purine metabolism, amino acid metabolism (glycine, serine, threonine, 
arginine, and proline), and energy metabolism (TCA cycle and glycolysis), were 
significantly changed by CKMT1 suppression in TF-1 and UCSD-AML1 cells (Figure 4G 
and 4H). This analysis revealed a significant (p value ≤ 0.05) decrease in intracellular ATP 
levels accompanied by an increase in ADP and AMP levels (Figure 4G). This increase in the 
ADP/ATP ratio induced by CK pathway inhibition was only observed in the four AML cell 
lines expressing high level of CKMT1 – TF-1, UT-7, UCSD-AML1, and Kasumi-3 – but not 
in those expressing low levels of CKMT1 (Figure 4I). Finally, activation of the creatine 
pathway by phospho-creatine rescued cyclocreatine-induced decrease in intracellular ATP 
level, suggesting that the creatine pathway may regulate ATP production in CKMT1-
expressing cells (Figure 4J).
To investigate this hypothesis, we evaluated the impact of creatine pathway inhibition on the 
respiration capacity of the mitochondria, the main organelles involved in ATP production. 
Measurement of mitochondrial oxygen consumption rate (OCR) reflects the capacity to 
produce ATP. Cyclocreatine treatment decreased basal mitochondrial respiration capacity in 
both TF-1 and UCSD-AML1 cells as well as the maximal mitochondrial respiration capacity 
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visualized after FCCP supplementation in UCSD-AML1 cells (Figure 4K). Co-treatment 
with phospho-creatine counteracted the effect of cyclocreatine and restored normal 
mitochondrial respiration capacity, suggesting that an active creatine pathway is required for 
promoting mitochondrial activity.
Finally, we overexpressed a wild-type (WT) or a metabolically inactive mutant form of 
CKMT1 (C316G21) in two AML cell lines, NB-4 and U937, that do not express endogenous 
CKMT1 (Supplementary Figure S5A). Wild-type, but not the C316G mutant form of 
CKMT1, conferred cyclocreatine sensitivity to these two cell types (Supplementary Figure 
S5B), and cyclocreatine treatment significantly reduced ATP production and basal 
mitochondrial respiration in cells expressing wild-type CKMT1 (Supplementary Figures 
S5C and S5D). All together, these data demonstrate that expression of CKMT1 renders 
mitochondria dependent on creatine pathway activity for ATP production.
Blockade of CK activity diminishes EVI1-expressing cell viability
To determine the transcriptional consequences of CK pathway inhibition in EVI1-expressing 
cells, we profiled three EVI1-expressing cell lines, TF-1, UT-7 and UCSD-AML1, treated 
with cyclocreatine for 24 hours using RNA sequencing (RNAseq). We identified 54 and 53 
genes significantly 1.5-fold upregulated and downregulated, respectively, compared to 
control treatment (Figure 5A). An open-ended enrichment analysis was next conducted 
using a relaxed cyclocreatine signature (defined based on the cut-offs SNR permutation p 
value ≤ 0.05, Benjamini-Hochberg false discovery rate (FDR) ≤ 0.05 and absolute fold 
change for log2 (FPKM) scores ≥ 0.5.) on the entire set of signatures from the c2 (MsigDB) 
and DMAP collections (Supplementary Tables S3 and S4). Gene sets related to cell cycle, 
energy metabolism and cell stemness were enriched in genes whose expression was 
suppressed by cyclocreatine and those related to cell differentiation were more enriched in 
genes whose downregulation was induced by both pro-differentiating agents and 
cyclocreatine. Finally, amino acid metabolism gene sets were more enriched in genes 
upregulated by cyclocreatine (Figure 5B, 5C, and Supplementary Table S5). At the 
intersection of the three enriched functional groups – cell cycle, cell stemness, and cell 
differentiation – a leading edge analysis isolated a core of ten highly significant genes 
downregulated by cyclocreatine treatment in the three lines profiled (Supplementary Figure 
S6A). We validated the transcriptional dowregulation of MYC and CCND1 in all of the 
EVI1-positive cell lines treated with cyclocreatine by real-time PCR (Supplementary Figure 
S6B). Cyclocreatine or CKMT1-directed shRNAs increased cell size and cell vacuolization 
(Figures 5D–5F). This was accompanied by a G0/G1 cell cycle arrest in UCSD-AML1 and 
Kasumi-3 cell lines while TF-1 and UT-7 underwent apoptosis (Figures 5G and 5H). Finally, 
expression of the immature cell surface marker CD117 decreased in response to 
cyclocreatine or CKMT1-direct shRNAs, and this was associated with inhibition of the serial 
replating activity of UCSD-AML1, TF-1, and UT-7 cells (Figures 5I and 5J).
Progression of EVI1-expressing AML depends on CKMT1
We next sought to investigate whether CKMT1 was required for EVI1-dependent AML 
disease development in vivo. Li et al. generated transplantable primary AMLs by performing 
retroviral insertional mutagenesis in Mx1-Cre; NrasG12D/+ mice22,23. We compared two 
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Nras mutant AMLs from this screen: NrasG12D + Evi1 contains a clonal Evi1 integration and 
expresses high transcript levels while the control NrasG12D AML does not. Immunoblot 
analysis revealed markedly elevated levels of Evi1 and Ckmt1 in the NrasG12D + Evi1 AML 
(Figure 6A), and this leukemia was also more sensitive to inhibition by cyclocreatine 
treatment than WT or NrasG12D bone marrow cells (Supplementary Figure S7A). To 
examine the oncogenic Evi1-dependency on Ckmt1 expression, we transduced NrasG12D 
and NrasG12D + Evi1 AML cells with a doxycycline-inducible non-targeting control (CT) or 
two Ckmt1-directed shRNAs. Venus-positive transduced cells were then sorted and injected 
into irradiated recipient mice. Once disease onset was detected, mice were treated with 
doxycycline to induce hairpin expression in tandem with an RFP reporter cassette, and 
knockdown was confirmed by immunoblot (Figure 6B). Mice transplanted with NrasG12D 
AML cells transduced with either control or Ckmt1-directed shRNAs, or NrasG12D + Evi1 
AML cells expressing shControl cells succumbed to aggressive AML with a median latency 
of approximately 20 days. By contrast, recipients of NRasG12D + Evi1 AML cells expressing 
either shCkmt1_2 or shCkmt1_3 exhibited attenuated disease and survived for 
approximately 40 days (Figure 6C). Splenomegaly and leukocytosis, which reflect the AML 
disease burden, were also markedly reduced in mice transplanted with NRasG12D + Evi1 
AML cells expressing either shCkmt1_2 or shCkmt1_3 (Figure 6D), and the splenic 
proportion of Gr-1+/Mac-1+ granulocytes was substantially reduced compared to NRasG12D 
+ Evi1 shControl mice (Figure 6E).
While all NrasG12D + Evi1 mice showed a recurrent expansion within the LinLow/Sca-1−/c-
Kit+/CD16/32+/CD34+ GMP compartment in comparison to wild-type mice, NrasG12D mice 
exhibited dominant growth of a less immature LinLow/Sca-1−/c-Kit+/CD16/32+/CD34− 
population (representative examples in Figure 6F). In NrasG12D mice, Ckmt1 knockdown 
did not alter the growth of the leukemic population compared to shControl mice. In 
recipients transplanted with NrasG12D + Evi1 AML cells, Ckmt1 suppression suppressed the 
expansion of the RFP+/Venus+ leukemic population from 58% in shControl mice to 2% in 
shCkmt1 group, thus reducing the overall growth advantage of the GMP fraction over MEP 
and CMP populations. To assess the effects of Ckmt1 deletion on normal hematopoiesis, 
CD45.2 bone marrow cells infected with shCT were transplanted into lethally irradiated 
recipient mice with an equal number of CD45.1 competitor bone marrow cells infected with 
Ckmt1-directed shRNAs (Supplementary Figure S7B). Chimerism was confirmed based on 
evaluation of the ratio of CD45.1 to CD45.2 in bone marrow of recipient mice. Reducing 
Ckmt1 expression did not alter the repopulating potential on normal hematopoietic cells in 
competitive transplantation assays, suggesting no toxic effect of Ckmt1 targeting in normal 
bone marrow cells (Supplementary Figure S7C).
Finally, we investigated the effects of either doxycycline-inducible CKMT1-directed 
shRNAs or cyclocreatine treatment on leukemia development in xenografts of EVI1-low 
U937-Luc and EVI1-high TF-1 CSF2+-Luc human AML cell lines. Leukemia burden was 
monitored in recipients treated therapeutically with doxycycline or cyclocreatine after 
detectable disease burden was increasing at day 8 in U937 cells and day 10 in TF-1 cells 
(Supplementary Figure S7D and S7E). Consistent with our in vivo analysis of primary 
murine Nras mutant AMLs, pharmacologic or genetic inhibition of the CKMT1-dependent 
pathway blocked disease progression and prolonged the survival of mice injected with TF-1 
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cells but not with U937 cells (Figures 6G and 6H). Co-treatment with phospho-creatine 
significantly rescued the effects of cyclocreatine in mice injected with TF-1 but had no effect 
in the U937 cell leukemia model (Figure 6I).
DISCUSSION
Here we found that overexpression of the zinc finger transcription factor EVI1 remodeled 
the metabolic landscape of immature hematopoietic cells, particularly by impacting cell 
energy-related pathways, arginine metabolism, and de novo synthesis of purines and 
pyrimidines. The broad transcriptional effects of EVI1 overexpression on these different 
metabolic pathways are reminiscent of a recent study which identified glutaminolysis as a 
critical pathway for T-cell acute lymphoblastic leukemia growth downstream of the 
hyperactivated, mutant form of the transcription factor NOTCH1 and as a key determinant of 
the response to anti-NOTCH1 therapies24. Other results suggest that glycolysis is important 
for MLL-AF9-driven AML maintenance and progression and that those leukemic cells are 
more sensitive to the inhibition of aerobic glycolysis than normal hematopoietic cells25. This 
supports the idea that the pro-leukemic effects of EVI1 expression in AML may be 
mediated, at least in part, by perturbations of cell metabolism and that targeting these 
metabolic dependencies may be promising therapeutic avenues in EVI1-positive leukemias.
Our results indicate a higher dependency of EVI1-positive leukemias, compared to other 
subgroups of AML, on the creatine kinase pathway. Creatine is one of the end products of 
the arginine pathway, which is altered upon EVI1 overexpression. In healthy cells, arginine 
can be produced by the ornithine-citrulline-arginine cycle. However, recent investigations 
identified that the majority of blasts from patients with AML are deficient in enzymes 
specialized in promoting this cycle and are therefore strongly reliant on extracellular 
arginine availability26,27. This study suggests that a constitutive blockade of the ornithine-
citrulline-arginine cycle would preferentially redirect transported arginine through other 
arginine-dependent metabolic pathways such as the creatine pathway. Interestingly, a 
mycoplasma-derived enzyme, ADI-PEG 20, that degrades extracellular arginine and thus 
prevents intracellular import of arginine showed good in vitro anti-leukemic efficacy in 19 
samples from a cohort of 38 primary AML patient samples28. From the entire cohort, only 
one AML sample harbored a translocation involving EVI1, and this sample was sensitive to 
ADI-PEG 20. This finding would be consistent with the dependency of EVI-positive AML 
on the creatine kinase pathway and suggests that EVI1-positive patients may also be good 
responders to a therapy targeting the import of arginine.
CKMT1 has two main functions in energy metabolism: it buffers the cellular ATP pool by 
maintaining cytosolic concentrations of phospho-creatine for high cellular energy demand to 
regenerate ATP, and it maintains an energy shuttle between sites of energy supply and sites 
of energy demand using the easily diffusible creatine29. Our results showed that CKMT1 
directly impacts mitochondrial respiration and ATP production. This is reminiscent of the 
role of hexokinases, another class of mitochondria-coupled enzymes that utilize ATP 
produced by mitochondria to catalyze conversion of glucose into glucose-6-phosphate, the 
first rate-limiting step of glycolysis30. In turn, the ADP formed from this reaction stimulates 
mitochondrial respiration31,32. Similarly, the increase of the creatine/phospho-creatine 
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interconversion rate subsequent to CKMT1 overexpression seems to regulate mitochondrial 
respiration and then influence mitochondrial ATP production. The expression of CKMT1 
alone is sufficient to reprogram mitochondrial activity, suggesting that CKMT1 upregulation 
itself may be one of the main contributors to metabolic perturbations that are necessary to 
the pro-leukemic effects of EVI1 in AML.
Although CKMT1 is ubiquitously expressed, several studies have shown that some cancer 
types, such as mesotheliomas, small cell lung and brain tumors, expressed higher CK protein 
levels which predict higher sensitivity to cyclocreatine33. Moreover, high CKMT1 
expression is a marker of poor prognosis for patients with breast cancer34. We established 
that EVI1 promotes CKMT1 expression by direct repression of the transcription factor 
RUNX1. A transcriptomic analysis of 269 patients with AML revealed that those who 
harbor t(8;21) or t(11q23) alterations exhibit a wild-type RUNX1 signature, while patients 
bearing del(7q)/7− or inv3/t(3;3) – responsible for EVI1 overexpression – express a RUNX1 
mutation-derived gene expression signature35. This corroborates our observation that 
CKMT1, whose expression is repressed by RUNX1, is predominantly upregulated in the 
EVI1-overexpressing leukemia subgroup.
The direct targeting of aberrant transcription factors as a therapeutic strategy remains a 
significant challenge in cancer therapy. An alternative approach is to target the unique 
liabilities engendered by the altered cellular circuitry present in these transcription-factor 
driven malignancies. To this end, we have integrated “omic” approaches to identify CKMT1 
as a druggable liability in EVI-positive AML. In considering the clinical translation of this 
finding, it is notable that cyclocreatine can be found in marketed nutritional and sports 
supplements. In addition, while not specifically for the mechanism of CKMT1 inhibition, 
but rather for use as a cell permeable analogue of creatine, cyclocreatine was granted orphan 
designation by the European Commission to Pharma Gateway AB, Sweden, in 2016 for the 
treatment of creatine deficiency syndromes. Despite enthusiasm about the likely safety of 
this molecule for multiple disease indications, clinical trials testing the safety and efficacy of 
cyclocreatine, however, will still need to be conducted. Another path forward for targeting 
CKMT1 might be the development of new selective agents targeting this enzyme. In 
summary, this study supports a potential therapeutic avenue for targeting the CK pathway in 
EVI1-positive AML, which remains one of the worst outcome subtypes of this disease.
ONLINE METHODS
Plasmids and shRNA Constructs
Empty and Evi GCDN vectors were a kind gift from Drs. Tomohiko Sato and Mineo 
Kurokawa (The University of Tokyo, Tōkyō, Japan). Empty and HA-tagged pHAGE-CMV-
CKMT1 and pHAGE-CMV-RUNX1 vectors were generated by enzyme-mediated site-
specific recombination between pENTR223-CKMT1 (Harvard PlasmID database, 
HsCD00372650) and pENTR223-RUNX1 (Harvard PlasmID database, HsCD00378663) 
donor vectors and pHAGE-CMV-HA destination vector (gift from Dr. J. Wade Harper, 
Harvard Medical School, Boston, MA, USA).
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shRNA constructs targeting human CKMT1 (shCKMT1_1 and shCKMT1_2), EVI1 
(shEVI1_1, shEVI1_2, shEVI1_4), CS (shCS_1, shCS_2, shCS3), SDHA (shSDHA_1, 
shSDHA_2, shSDHA_3), or RUNX1 (shRUNX1_2, shRUNX1_6) – sequences listed below 
– were designed by adapting BIOPREDsi small interfering RNA predictions. shRNAs were 
cloned into the TRMPVIR retroviral vector36, containing a miR30 expression cassette, as 
116-nt XhoI–EcoRI fragments, which were generated by amplifying 97-mer 
oligonucleotides (Invitrogen) using 5′miR30-XhoI 
(TACAATACTCGAGAAGGTATATTGCTGTTGACAGTGAGCG) and 3′miR30-EcoRI 
(ACTTAGAAGAATTCCGAGGCAGTAGGCA) primers and the Vent polymerase kit 
(Invitrogen) with the following conditions: 50 μl reaction containing 0.05 ng oligonucleotide 
template, 1× Vent buffer, 0.3 mM of each dNTP, 0.8 μM of each primer, and 1.25 U Vent 
polymerase; cycling: 94 °C for 3 min; 35 cycles of 94 °C for 30 s, 54 °C for 30 s, and 75 °C 
for 20 s; 75 °C for 5 min.
Designation Species Accession Number Target Sequence
shCKMT1_1 Homo Sapiens NM 020990.3 ATCACCCGTGTATGATCCTCC
shCKMT1_2 Homo Sapiens NM_020990.3 TTTACTGGCATCTAGATCCGT
shCS_1 Homo Sapiens NM 004077.2 ATCGCGGATCAGTCTTCCTTA
shCS_2 Homo Sapiens NM 004077.2 AAGAACTGATGTTTCATAGAC
shCS_3 Homo Sapiens NM_004077.2 TGTAACAGCTGCACTGAGCTG
shEVI1_1 Homo Sapiens NM 001105077.31 NM 005241.3|
NM 001105078.3|NM 004991.3|
NM 001163999.1|NM 
001164000.1
TTTCTGTGAAGTAAGCATCTT
shEVI1_2 Homo Sapiens NM 001105077.31 NM 005241.3|
NM 001105078.3|NM 004991.3|
NM 001163999.1|NM 
001164000.1
TTGCACTTGATTTGGGTTCTG
shEVI1_4 Homo Sapiens NM_001105077.31 
NM_005241.3 | NM_001105078.3 
| NM_004991.31 
NM_001163999.1| 
NM_001164000.1
TTCCAGTT CAGAATGAGGCGA
shRUNX1_2 Homo Sapiens NM 001001890.2| NM 001754.4|
NM 001122607.1
TGATCATCTAGTTTCTGCCGAT
shRUNX1_6 Homo Sapiens NM 001001890.2| NM 001754.4|
NM 001122607.1
TCCACTGTGATTTTGATGGCTC
shSDHA_1 Homo Sapiens NM_004168.2 CAGATGCCCTCTTGTTCCCAT
shSDHA_2 Homo Sapiens NM_004168.2 ATGACTCTTCGATGCTCAGGG
shSDHA_3 Homo Sapiens NM_004168.2 AACAGTGTTCTTTGCTCTTAT
shControl AGGAATTATAATGCTTATCTA
shRNA constructs targeting murine Ckmt1 (shCkmt1_2 and shCkmt1_3) were purchased 
from GE Healthcare and were subcloned from the GIPZ vector into the TRIPZ-Venus 
lentiviral vector. The TRIPZ-Venus vector was designed by substitution in the TRIPZ vector 
(GE Healthcare), of the puromycin resistance cassette for the sequence encoding the yellow-
green fluorescent protein Venus reporter isolated from the TRMPVIR vector. Non-inducible 
human CKMT1-directed shRNAs (CKMT1_3 and CKMT1_4) and murine Ckmt1-directed 
shRNAs used for the in vivo chimerism assay were purchased from TransOMIC Technology 
Inc.
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For virus production, 12 μg of the above plasmids and 6 μg ψ-eco (for retroviral infection of 
murine cells), 6 μg pCMV-GAG/POL and pCMV-VSVG (for retroviral infection of human 
cells), or 6 μg pCMV8.9 or psPAX2 and pCMV-VSVG (for lentiviral infection of human 
and murine cells) packaging vectors were transfected into the 293T packaging cell line using 
X-tremeGENE 9 (Roche), and the resulting viral supernatants were harvested as previously 
described37. The lentiviral viruses were then concentrated using PEG-it™ Virus 
Precipitation Solution (SBI System Biosciences).
Pooled shRNA Screening
A custom library of 361 hairpins directed against 67 human genes involved in glycolysis, 
pentose phosphate pathway, TCA cycle, and related metabolic pathways with at least 3 
hairpins per gene, was cloned into a retroviral pMLP2.1 vector and was purchased from 
TransOMIC Technology Inc. To preserve library complexity, a minimum of 1000-fold 
coverage of the shRNA library was maintained at each step of the screen. Two series of 
quadruplicates, from TF-1 and UCSD-AML1 cells, were spin-infected using plates coated 
with 10 μg/mL retronectin (Takara) per the manufacturer’s instructions. Fresh viral 
supernatant was added onto each retronectin-coated well before spinning for two hours at 
2000g at 32°C to allow virus binding to the retronectin. 7.5×106 cells in 6 mL transplant 
media containing 5 μg/mL polybrene (Sigma) and 7.5 mM HEPES buffer (Sigma) were then 
seeded into each of these wells and centrifuged for 1 hour at 1800g to promote cell 
transduction. The final transduction rate estimated was between 5% and 10% of GFP-
positive cells. Cells were expanded for 48 hours before selection with 1 μg/ml puromycin. 
At 72 hours post-puromycin selection, half of the volume of each quadruplicate was pelleted 
and frozen down to constitute the day 0 time point, and cells were maintained in culture and 
split every two days to keep at least 6×106 cells per replicate until day 36. Genomic DNA 
was isolated by proteinase K digestion and isopropanol precipitation from each pellet at day 
0 and day 36 time-points. The antisense strand of shRNA was amplified from genomic DNA 
using primers that include 1-basepair mutations to barcode individual samples. Hairpins 
were amplified in multiple 50 μl reactions using HotStar Taq (Qiagen). After PCR 
amplification, samples were pooled and prepared for sequencing with Illumina’s genomic 
adaptor kit. At least 41 bases of the PCR product were sequenced with an Illumina HiSeq 
2000 machine. shRNAs with less than 100 reads in the input sample were excluded from 
further analysis, and read numbers for each shRNA were normalized to the total read 
numbers per sample to allow for cross-comparison between samples. We then compared 
using an EdgeR/RIGER method the hairpin representation between day 0 and day 36 and 
thus identified genes whose depletion blocked or enhanced cell proliferation. EdgeR (R/
Bioconductor v.3.3 package38) provided the statistical analysis of count data from the day 0 
versus day 36 time-points per cell lines. Next, the RNAi gene enrichment ranking (RIGER) 
score was given by examination of the position of each hairpin targeting each gene in the full 
ranked list of the 361 shRNAs. The enrichment scores and the gene ranking were finally 
computed based on the RIGER v.0.1 module39 available from the GENE-E platform (http://
www.broadinstitute.org/cancer/software/GENE-E/). The GENE-E platform is now replaced 
by the Morpheus platform which is available at the same URL as GENE-E.
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Metabolite Profiling for Steady-state and Targeted Flux Analyses
To determine the relative levels of intracellular metabolites, extracts were prepared and 
analyzed by LC/MS/MS. Twenty-four hours after sorting and 16 hours prior to metabolite 
extraction, 7.5×106 cells were plated in triplicate in an incubation media: DMEM media 
with no glucose, no glutamine, and no sodium pyruvate (Gibco) supplemented with 1 g/L D-
glucose (Sigma), 1.5 mM L-glutamine (Sigma), 5 mM sodium pyruvate (ThermoFisher 
Scientific), 4 g/L BSA (Sigma), 1 μg/ml insulin (#91077, Sigma), 30 μg/mL transferrin 
(#T0665, Sigma), 20 ng/ml IL-3 (#213-13, Peprotech), 20 ng/ml IL-6 (#216-16, Peprotech), 
100 ng/ml FLT3-Ligand (#250-31L, Peprotech), and 100 ng/ml SCF (#250-03, Peprotech). 
For L-Arginine 13C6 flux studies, cells were washed twice with PBS and then incubated in 
DMEM no glutamine, no lysine, and no arginine media supplemented with 466 μM L-
Arginine 13C6, 1 mM Lysine, 1.5 mM L-glutamine, 5 mM sodium pyruvate, and 10% 
dialyzed FBS. Metabolites were extracted on dry ice with 4 mL of 80% methanol (−80°C), 
as described previously40. Insoluble material was pelleted by centrifugation at 3000g for 5 
min, followed by two subsequent extractions of the insoluble pellet with 0.5 ml of 80% 
methanol, with centrifugation at 16000g for 5 min. The 5 ml metabolite extract from the 
pooled supernatants was dried down under nitrogen gas using an N-EVAP (Organomation 
Associates, Inc).
Dried pellets were re-suspended using 20 μL HPLC grade water for mass spectrometry. 10 
μl were injected and analyzed using a 5500 QTRAP triple quadrupole mass spectrometer 
(AB/SCIEX, BIDMC Mass Spec Core, Boston, MA, USA) coupled to a Prominence UFLC 
HPLC system (Shimadzu) via selected reaction monitoring (SRM) of a total of 292 
endogenous water soluble metabolites for steady-state analyses of samples. Some 
metabolites were targeted in both positive and negative ion mode for a total of 391 SRM 
transitions using pos/neg polarity switching. ESI voltage was +4900V in positive ion mode 
and –4500V in negative ion mode. The dwell time was 3 ms per SRM transition and the total 
cycle time was 1.55 seconds. Approximately 10–14 data points were acquired per detected 
metabolite. Samples were delivered to the MS via normal phase chromatography using a 4.6 
mm i.d × 10 cm Amide Xbridge HILIC column (Waters Corp.) at 350 μL/min. Gradients 
were run starting from 85% buffer B (HPLC grade acetonitrile) to 42% B from 0–5 minutes; 
42% B to 0% B from 5–16 minutes; 0% B was held from 16–24 minutes; 0% B to 85% B 
from 24–25 minutes; 85% B was held for 7 minutes to re-equilibrate the column. Buffer A 
was comprised of 20 mM ammonium hydroxide/20 mM ammonium acetate (pH=9.0) in 
95:5 water:acetonitrile. Peak areas from the total ion current for each metabolite SRM 
transition were integrated using MultiQuant v2.0 software (AB/SCIEX). For stable isotope 
labeling experiments, custom SRMs were created for expected 13C incorporation in various 
forms for targeted LC/MS/MS. Peak areas of metabolites detected by mass spectrometry 
were normalized to median and then normalized to protein concentrations. A Student’s t-test 
was performed to assess significance of all pairwise comparisons. All data are log2-
transformed and normalized against the average control condition. No or small variations in 
metabolite production compared to average control condition appears closest to the white 
color on the heatmap. Decreased or increased metabolite production compared to the 
average control condition is represented by a gradient of color from blue to red respectively. 
The MetaboAnalyst software (www.metaboanalyst.ca) was used to perform pathway 
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enrichment analysis on the set of top metabolites hits identified by steady-state profiling. No 
specific manual settings were needed to analyze the list of metabolites.
ChIP-sequencing and ChIP-qPCR
A Runx1 gene track generated by ChIP-sequencing for the analysis of murine Evi1 binding 
peaks was obtained from Dr. Archibald S. Perkins (University of Rochester Medical Center, 
New-York, NY, USA). The human RUNX1 gene track was obtained from publically 
available ChIP-sequencing data generated by Bard-Chapeau et al.19. The conservation score 
between species was computed based on phasCons data for hg18 and mm941. Gene tracks 
and EVI1-binding peaks were aligned using IGV software42.
ChIP-qPCR was performed as described by Bernt et al.43. Briefly, crosslinking was 
performed in cell culture medium containing 1% formaldehyde with gentle rotation for 5 
minutes at room temperature. Fixation was stopped by the addition of glycine (125 mM final 
concentration). Fixed cells were washed twice in ice-cold PBS and then resuspended in SDS 
lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris-HCl, pH 8.1, supplemented with 
Complete-mini-protease inhibitor cocktail (Roche)). Chromatin was sheared to 
approximately 200bp fragments by Covaris ultra-sonication and immunoprecipitated. 
Precipitates were washed sequentially with ice cold low salt wash (0.1% SDS, 1% Triton-
X-100, 2 mM EDTA, 20 mM Tris-HCl, pH 8.1, 150 mM NaCl), high salt wash (0.1% SDS, 
1% Triton-X-100, 2 mM EDTA, 20 mM Tris-HCl, pH 8.1, 500 mM NaCl), LiCl wash (0.25 
M LiCl, 1% IGEPAL CA-630, 1% deoxycholic acid, 1 mM EDTA, 10 mM Tris-HCl, pH 
8.1) and TE wash (1 mM EDTA, 10 mM Tris-HCl, pH 8.1) and eluted in elution buffer (1% 
SDS, 0.1M NaHCO3). Eluted DNA fragments were analyzed by qPCR. Primers used for 
ChIP-qPCR are listed below.
Targets Species Forward Reverse
Runxl Mus Musculus CTCCCTCCCTCTCTCCTCTATTAAA GAGTTCTTGTCTTTCTGCGTCATG
Ckmtl Mus Musculus GTCTGAGTATGCACTTCGCAAAA GGTCATCAGGGAGTCTCTGTCTTC
CKMT1 Homo Sapiens AGACCTGTGCCTGCCTGTTC GGAGGAGAAGGTAAAGTGAGGTGAA
Western Immunoblotting
Western immunoblotting was performed as described previously44 using cell lysates 
normalized for total protein content. Lysates were boiled in Laemmli sample buffer and run 
on SDS–polyacrylamide gel electrophoresis (PAGE) prior to transfer to nitrocellulose 
membranes, and immunoblotting. A list of antibodies used for western immunoblotting is 
listed below.
Flow Cytometry
Cell lines were washed in PBS-0.1% BSA-2 mM EDTA before a 45 minute incubation with 
an anti-human CD117 antibody. Cells were then washed twice with PBS containing 0.1% 
BSA and 2 mM EDTA before analysis with BC FACScanto II (BD Biosciences).
Primary patient AML cells were washed in PBS containing 0.1% BSA and 2 mM EDTA 
before a 45-minute incubation with a combination of anti-human PE-Cy7 CD13 and CD33 
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(used at 1/50) or PE-Cy7 isotype control antibodies. Cells were then washed twice with 
PBS-0.1% BSA-2 mM EDTA before a 20-minute fixation with BD Cytofix/CytoPerm 
Fixation and Permeabilization Solution (BD Biosciences). Cells were then washed three 
times with BD Perm/Wash Buffer and incubated for 45 minutes at 4°C with a non-
conjugated anti-human EVI1 antibody (used at 1/50), or the corresponding isotype control 
antibody. Cells were washed three times with Perm/Wash Buffer and were incubated for 35 
minutes with an Alexa Fluor 488 goat anti-rabbit IgG antibody used at 1/500 (Invitrogen). 
Cells were washed three times in Perm/Wash Buffer and analyzed using a BD FACSCanto II 
analyzer. To account for any background fluorescence, the EVI1 mean fluorescence level 
was normalized to the mean fluorescence level of its corresponding isotype control. This 
normalized value was then scaled for each patient using the Z-Score calculation across all 
patient samples.
Murine bone marrow and spleen were collected from each organ, washed with PBS 
containing 0.1% BSA and 2 mM EDTA and lysed for 10 minutes with red blood cell lysis 
buffer (Sigma). After two washing steps with PBS containing 0.1% BSA and 2 mM EDTA, 
bone marrow cells were stained for 30 minutes at 4°C with a combination of anti-lineage 
cocktail, Sca-1, c-KIT, CD16/32 and CD34 antibodies and spleen cells were incubated for 5 
minutes at 4°C with mouse BD Fc Block™ (BD Biosciences) before staining with the 
combination of Mac-1/Gr-1 antibodies. Stained cell subpopulations were analyzed with BD 
LSR-II analyzer (BD Biosciences).
A list of antibodies used for western immunoblotting and flow cytometry is listed below.
Targets Conjugate References Manufacturer
ACTIN Non MS-1295-P Neomarkers
CD5 APC 17-0051 eBioscience
CD13 PE-Cy7 25-0138-42 eBioscience
CD16/32 PerCP-Cy5.5 45-0161-82 eBioscience
CD33 PE-Cy7 25-0338-42 eBioscience
CD34 eFluor 450 48-0341-82 eBioscience
CD45.1 PE-Cy7 25-0453-82 eBioscience
CD45.2 APC 17-0454-82 eBioscience
CD45R APC 17-0452 eBioscience
CD117 PE-Cy7 313212 BioLegend
CD127 APC 17-1271 eBioscience
c-KIT PE-Cy5 105810 BioLegend
CKMT1 Non H00001159M16 Abnova
CKMT1 Non H00001159-D01 Abnova
CS Non 14309S Cell Signaling Technology
EVI1 Non 2593 Cell Signaling Technology
Evi1 Non Custom Dr. Archibald Perkins
GR-1 APC 17-5931-81 eBioscience
GAPDH Non sc-25778 Santa-Cruz Biotechnology
H3K4Me3 Non Ab8580 Abcam
H3K27Ac Non Ab4729 Abcam
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H3K27Me3 Non Ab6002 Abcam
HSP60 Non sc-1722 Santa-Cruz Biotechnology
HSP90 Non sc-13119 Santa-Cruz Biotechnology
Lineage APC BDB558074 BD Biosciences
Mac-1 PE-Cy7 101216 BioLegend
RUNX1 Non Ab23980 Abcam
RUNX1 Non 8529 Cell Signaling Technology
Sca-1 PE-Cy7 25-5981-82 eBioscience
SDHA Non 11998P Cell Signaling Technology
VINCULIN Non Ab18058 Abcam
Genome-wide Expression Analysis
Genome Profiling of Evi1-overexpressing Murine Progenitor Cells—eGFP-
positive control and Evi1-overexpressing progenitor cells were sorted and total RNA was 
extracted and profiled using the GeneChip Mouse Gene 1.0 ST Array from Affymetrix 
(GSE3910316).
Comparative Marker and GSEA Analyses: The 6 samples in the GSE39103 data 
available from the Gene Expression Omnibus (GEO) repository (http://
www.ncbi.nlm.nih.gov/geo/) were separated into 2 groups: control versus Evi1-
overexpressing samples. The Comparative Marker Selection module from GenePattern 
v3.9.345 was used to identify individual genes differentially expressed between the two 
groups. A permutation p value ≤ 0.05, a Benjamini–Hochberg false discovery rate (FDR) ≤ 
0.05 accounting for multiple hypothesis testing, and an absolute fold change ≥ 2 served as 
cutoff for significant genes. The Gene Set Enrichment Analysis (GSEA) v.2.1.0 
software46,47 was used to identify pathways, or groups of functionally related genes, 
deregulated by Evi1 overexpression. The goal of GSEA is to identify groups of genes 
sharing common biologic function (gene sets), which are distributed at the top or at the 
bottom of the ranked list of differentially expressed genes. The significance of the 
enrichment score is estimated on the basis of a permutation p value and adjusted for multiple 
hypotheses testing through FDR. The set of differentially expressed genes accounting for the 
enrichment signal is called the leading edge. GSEA was run on the c2 collection of 4725 
curated gene sets from MSigDB v.5.0 (http://software.broadinstitute.org/gsea/msigdb/). 
Gene sets with less than 15 genes or more than 500 genes were excluded from the analysis. 
Gene sets with a nominal p value ≤ 0.05 and FDR ≤ 0.25 were considered significant. The 
gene ranking metric in the weighted enrichment score was the 2-sided SNR, and the p values 
were calculated using 1,000 permutations of the phenotype.
Metabolic Network: Each metabolic gene deregulated upon Evi1 overexpression was 
assigned to a functional group based on the c2 collection from MSigDB (http://
www.genomespace.org). The enrichment results were visualized with the Enrichment Map 
module,48,49 which organizes the significant gene sets into a network called an “enrichment 
map.” In the enrichment map, the nodes correspond to gene sets and the edges reflect 
significant overlap between the nodes according to a two-tailed Fisher exact test. The hubs 
correspond to collections of gene sets with a unifying class label according to gene ontology 
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(GO) biologic processes. The size of the nodes is correlated with the number of genes in the 
gene set.
Gene Expression Profiling of Cyclocreatine Treatment—TF-1, UT-7 and UCSD-
AML1 cells were treated in quadruplicate with either vehicle or 3 mM cyclocreatine for 24 
hours. Total RNA was extracted and profiled by RNA sequencing (HiSeq, Illumina) at the 
BioMicroCenter, Massachusetts Institute of Technology (Cambridge, MA, USA). The total 
number of reads for individual samples ranged from 44 to 48 Mb. Quality control tests for 
the unmapped reads were performed using the FASTQC software (http://
www.bioinformatics.babraham.ac.uk/projects/fastqc/). The reads were aligned to the 
GRCh37 (hg19) GENCODE v17 annotated human reference genome by using TopHat250. 
FPKM scores for genes were computed based on the RSEM R software package51. 
Expression data was evaluated as log2 (FPKM). The significance of the differential 
expression between the control and cyclocreatine treatment phenotypes was estimated using 
the EBSeq method implemented in R (Bioconductor v.3.352), based on the significance 
cutoff 0.05 for the posterior probability. The aligned RNASeq data is available at the GEO 
repository (GSE86151).
Comparative Marker Analysis: The 24 samples available in the RNAseq data were 
separated into two groups: 12 =vehicle-treated and 12 =cyclocreatine treated. The 
Comparative Marker Selection module from GenePattern v.3.9.345 was employed to identify 
individual genes that were differentially expressed between the two conditions. The analysis 
was performed by applying a 2-sided Signal-to-Noise Ratio (SNR) test followed by 1000 
permutations of phenotype labels. The settings for the SNR parameters were log-
transformed-data:no, complete:no, balanced:no, smooth p values: yes.
A “core” cyclocreatine signature consisting of 54 genes upregulated and of 53 genes 
downregulated between the vehicle and cyclocreatine-treated samples was defined based on 
the cut-offs SNR permutation p value ≤ 0.05, Benjamini-Hochberg false discovery rate 
(FDR) ≤ 0.05, and absolute fold change for log2 (FPKM) scores ≥ 1.5. In addition, a 
“relaxed” cyclocreatine signature consisting of 366 upregulated and 474 downregulated 
genes between the two conditions was defined based on the cut-offs SNR permutation p 
value ≤ 0.05, Benjamini-Hochberg false discovery rate (FDR) ≤ 0.05 and absolute fold 
change for log2 (FPKM) scores ≥ 0.5. The “core” cyclocreatine signature is presented in 
Supplementary Tables S3 and S4.
GSEA analysis and Scatter Plot: The Gene Set Enrichment Analysis (GSEA v2.1.0) 
software46,47 was used to identify functional associations of the molecular phenotypes 
induced by cyclocreatine with a compendia of gene signatures including the MSigDB 
v5.047,53 collections c2 of 4,725 curated gene sets and c6 of 189 oncogenic signatures, the 
DMAP collection of hematopoietic lineage differentiation signatures53, and with four AML 
differentiation gene signatures available from Gene Expression Omnibus (GEO) database: 
Vitamin D- and PMA-induced differentiation signatures (accession no. GSE99554); JQ1-
induced differentiation signature (accession no. GSE2979955), and DOT1L inhibitor-
induced differentiation signature (accession no. GSE2982856). Gene sets with less than 15 
genes or more than 500 genes were excluded from the analysis. Gene sets with an FDR ≤ 
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0.25 and a nominal p value ≤ 0.05 were considered significant hits. The results were plotted 
on volcano plots and visualized on a functional network called an “enrichment map”. In the 
enrichment map, the nodes correspond to gene sets and the edges reflect significant overlap 
between the nodes according to a two-tailed Fisher exact test. The size of the nodes is 
correlated with the gene set enrichment significance (−log10 (p value)). The hubs 
correspond to collections of gene sets with a unifying functional category label.
In Silico Tests for CKMT1 High Versus CKMT1 Low Expression in Primary AML Samples
The in silico test used to determine the proportion of EVI1high/RUNX1low, EVI1high/
RUNX1high, EVI1low/RUNX1low, and EVI1low/RUNX1high patients exhibiting high CKMT1 
versus low CKMT1 expression levels was carried out on the Affymetrix U133 Plus2 gene 
expression data GSE14468857 (526 AML samples) and GSE1035858 (279 AML samples). 
Data were downloaded from the InSilico DB Genomic Datasets Hub (http://
www.genomespace.org). EVI1, RUNX1, and CKMT1 expression levels were computed for 
each sample of these two cohorts and were further transformed into a z-score by subtracting 
the average of the EVI1, RUNX1, and CKMT1 expression levels assigned to all other 
samples and by dividing the result to their standard deviation. For each patient, high versus 
low EVI1, RUNX1, and CKMT1 expression levels were evaluated based on the absolute cut-
off of a z-score ≥ 0.58 is high expression and a z-score ≤ −0.58 is low expression. The 
significance of the differences between the proportions of patients with CKMT1 high versus 
low expression within patient subgroups with high and low EVI1 and RUNX1 expressions 
was estimated by applying the two-tailed Fisher’s Exact Test implemented in the function 
fisher.test (library stats, R 3.2, http://cran.r-project.org/).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. EVI1 overexpression imparts new metabolic dependencies on AML cells
(A) Quantitative comparison by GSEA of the c2 collection of curated gene sets available 
from MSigDB v.5.0 for murine LinLow Evi1-overexpressing versus control bone marrow 
samples (GSE 34729). Data are presented as a volcano plot of −log10 (FDR) versus the 
normalized enrichment score for each evaluated gene set. Triangles indicate sets related to 
proliferation (green), cell differentiation (blue), and metabolism (red), and gray dots indicate 
all other c2 gene sets.
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(B) Metabolic network showing gene sets altered in the Evi1 overexpression signature 
generated from GSE 34729. Black, dark grey, light grey, and white colors indicate an 
enrichment odds ratio (OR) above 3, between 2 and 3, between 1 and 2, and below 1, 
respectively.
(C) Pathway analysis integrating enrichment and pathway topology analyses 
(MetaboAnalyst) of the steady-state metabolite profile from control versus Evi1-
overexpressing LinLow murine bone marrow cells. Top 15 out of a total of 45 metabolic 
pathways are represented based on a FDR ≤ 0.1 and p value ≤ 0.05. “Hits” represents the 
number of metabolites that scored in the steady-state profile and “Total” represents the 
number of metabolites present in the given metabolic pathway. Metabolic pathways with a - 
log10 (FDR) ≥ 1.5 are depicted in red, 1 ≤ − log10 (FDR) < 1.5 are in orange, and − log10 
(FDR) < 1 in beige.
(D) Scatterplot of hits significantly depleted (in blue) or enriched (in red) from an shRNA 
library targeting 67 metabolism-related genes in the human TF-1 (top) and UCSD-AML1 
(bottom) cell lines. Hits which did not score are depicted in black. Data are presented as 
volcano plots of −log10 (FDR) versus the RIGER enrichment score for each gene.
(E) Heatmap of the metabolism genes differentially expressed by genomic profiling in GSE 
34729 upon Evi1 overexpression in LinLow bone marrow cells (left panel), and heatmap of 
genes either depleted (in blue) or enriched (in red) in the shRNA screen in TF-1 and UCSD-
AML1 cells (right panel). Shown in blue text are genes both upregulated upon Evi1 
overexpression and depleted in the shRNA screen. CT, control. Each column for each 
condition represents a technical replicate (n=3 per condition).
(F) Growth of TF-1 cells infected with hairpins directed against either CKMT1, SDHA, or 
CS (left panel). Immunoblot confirming shRNA target knockdown (right panel). shCT, 
control shRNA. Error bars represent mean ± SD. * and # p value ≤ 0.05 was calculated on 
the latest time point using a nonparametric Kruskall-Wallis test and Dunn’s multiple 
comparisons test. Data are representative of two independent experiments.
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Figure 2. EVI1-positive cells highly express and are dependent on CKMT1
(A) Immunoblot for EVI1, CKMT1, and HSP60 (loading control) from a panel of human 
AML cell lines with high or low EVI1 expression.
(B-C) Creatine kinase activity (B) and distribution of IC50 (C) for human EVI1 high versus 
low cell lines treated with cyclocreatine (Ccr). p value calculated using nonparametric 
Mann-Whitney test. Error bars represent mean ± SD of 8 low EVI1-expressing and four high 
EVI1-expressing human cell lines.
(D) Eleven human AML cell lines were infected with two CKMT1-directed miR30-shRNAs. 
Growth after treatment with 0.5 μg/ml doxycycline is normalized to the control shRNA and 
shown relative to day 0 (time of seeding), with error bars representing the mean ± SD of 
seven technical replicates. Each experiment in A–D was performed at least two independent 
times.
(E) Z Score normalization of EVI1 expression across a panel of CD13/33-gated bone 
marrow cells from 68 patient AML samples. Red bars indicate the four patients with the 
highest EVI1 expression level.
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(F) Immunoblot for EVI1, CKMT1, and GAPDH (loading control) from bone marrow 
samples sub-selected from panel (E).
(G) Distribution of IC50 for EVI1 high versus low patient samples in response to treatment 
with cyclocreatine (Ccr). Red squares represent the four patient samples from panel (F) 
highlighted in red. p value calculated using nonparametric Mann-Whitney test. Error bars 
represent mean ± SD of 10 low EVI1-expressing and four high EVI1-expressing human 
primary samples.
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Figure 3. EVI1-mediated RUNX1 downregulation promotes CKMT1 expression
(A–B) Immunoblot for Evi1, Ckmt1 and Gapdh (A) and qRT-PCR for Ckmt1 expression (B) 
from LinLow, c-Kit+ murine bone marrow cells infected with an empty or Evi1-encoding 
construct. Error bars represent the mean ± SD of four technical replicates. * p value ≤ 0.05 
in comparison with empty control vector calculated using a Mann-Whitney test.
(C) qRT-PCR for CKMT1 expression level in human TF-1 and UCSD-AML1 cells infected 
with shControl (shCT) or three EVI1-targeting shRNAs. Error bars represent mean ± SD of 
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four technical replicates. * and # p value ≤ 0.05 in comparison with shCT calculated using a 
Mann-Whitney test.
(D) Luciferase reporter assay from human 293E cells co-expressing a vector encoding EVI1, 
and wild-type or several truncated forms of the human CKMT1 promoter flanking a 
luciferase cassette.
(E) Luciferase reporter assay from human 293E cells co-expressing a vector encoding EVI1 
and a luciferase-flanked human CKMT1 promoter either wild-type or deleted for the 
RUNX1-binding site.
(F) Luciferase reporter assay from human 293E cells co-expressing vectors encoding EVI1 
and RUNX1.
(G) Immunoblot for EVI1, RUNX1, CKMT1, and HSP60 (loading control) from human 
TF-1 cells infected with the indicated combinations of EVI1- and RUNX1-directed shRNAs.
(H) Representation of EVI1 binding peaks on RUNX1 gene tracks available from two ChIP-
sequencing experiments performed by Bard-Chapeau et al.19 and Glass et al.20.
(I-L) LinLow, c-Kit+ murine bone marrow cells overexpressing a vector encoding Evi1 (I–J), 
or human UCSD-AML1 cells infected with shControl (shCT) and three EVI1-directed 
shRNAs (K), or human UCSD-AML1 cells infected with combinations of EVI1- and 
RUNX1-directed shRNAs (L) following ChIP with the indicated ChIP antibodies (ChIP Ab) 
and qPCR on the indicated promoter regions. Results are represented as fold enrichment 
over input.
(D–L) Error bars represent mean ± SD of three technical replicates.* p value ≤ 0.05 
calculated using a Welch’s t-test. Each experiment in A–L was performed at least two 
independent times.
(M) TF-1-Luc cells engineered to overexpress CSF2 for efficient engraftment were infected 
with a combination of two EVI1- and one RUNX1-directed shRNAs before tail vein 
injection. Bioluminescence was quantified weekly as a measure of disease burden. Data are 
represented as mean ± SEM of 5 mice per cohort. * p value ≤ 0.05 was calculated on the 
latest time point using nonparametric Mann-Whitney test.
(N) Bar graph showing the number of primary patient AML samples with either EVI1high/
RUNX1low, EVI1high/RUNX1high, EVI1low/RUNX1low, or EVI1low/RUNX1high expression 
and displaying CKMT1 high versus low expression level (absolute cut-off of a z-score ≥ 
0.58 is high expression and a z-score ≤ − 0.58 is low expression) in two cohorts: GSE14468 
and GSE10358. p value calculated using a Fisher exact test.
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Figure 4. Blockade of the arginine-creatine pathway upon CKMT1 inhibition impairs both 
mitochondrial respiration and ATP production in EVI1-positive AML cells
(A) Schematic of arginine metabolism and enzymes involved in this process.
(B–C) Heatmaps of metabolite products of arginine metabolism that are differentially 
regulated in human UCSD-AML1 cells infected with either control (shCT) or CKMT1-
directed shRNAs (B) or in human TF-1 cells treated with 3 mM cyclocreatine (Ccr) for 12 
hours in combination with 1 mM phospho-creatine (P-Cr) (C) before a 30-min pulse labeling 
with L-Arginine 13C6. Metabolites scoring with a p value ≤ 0.05 are shown as log2 fold 
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change normalized to the average control condition. Each column for each condition 
represents a technical replicate (n=3 per condition).
(D–E) Growth inhibition of human TF-1 and UCSD-AML1 cells treated with increasing 
concentrations of cyclocreatine (Ccr) (D) or infected with control (shCT) or CKMT1-
directed shRNAs (E) in combination with 1 mM phospho-creatine (P-Cr). Error bars 
represent mean ± SD of five technical replicates.* p value ≤ 0.05 in comparison with 
shControl calculated using a Mann-Whitney test.
(F) Colony-forming assay for 5 rounds of serial replating from control or Evi1-
overexpressing murine LinLow, c-Kit+ bone marrow cells treated with 3 mM cyclocreatine 
(Ccr) in combination with 1 mM phospho-creatine (P-Cr). # p value ≤ 0.05 calculated using 
Welch’s t-test in comparison with the control condition. Error bars represent mean ± SEM of 
three technical replicates.
(G) Heatmap of the top upregulated or downregulated metabolites (p value ≤ 0.05 and 
absolute log2 fold change ≥ 1.5 in at least one of the two CKMT1-directed shRNAs 
condition versus average shControl condition) identified by steady-state metabolism 
profiling in human TF-1 and UCSD-AML1 cells infected with either control (shCT) or two 
CKMT1-directed shRNAs. Each column for each condition represents a technical replicate 
(n=3 per condition in two individual human EVI1-positive cell lines).
(H) Pathway analysis integrating enrichment and pathway topology analyses 
(MetaboAnalyst) of the list of top metabolites from panel (G). Top enriched metabolic 
pathways are represented based on a FDR ≤ 0.25 and p value ≤ 0.05. “Hits” represents the 
number of metabolites that scored in the steady-state profile and “Total” represents the 
number of metabolites present in the given metabolic pathway. Metabolic pathways with a − 
log10 (FDR) ≥ 1.5 are depicted in red, 1 ≤ − log10 (FDR) < 1.5 are in orange, and − log10 
(FDR) < 1 in beige.
(I) ADP / ATP ratio in a panel of 12 human AML cell lines treated with 5 mM cyclocreatine 
(Ccr) for 12 hours. * p value ≤ 0.05 in comparison with the control condition calculated 
using a Mann-Whitney test. Error bars represent mean ± SD of four technical replicates.
(J) Intracellular ATP level in the indicated human EVI1-positive AML cell lines treated with 
5 mM cyclocreatine (Ccr) in combination with 1 mM phospho-creatine (P-Cr) for 12 hours. 
* and # p value ≤ 0.05 calculated using a Mann-Whitney test in comparison with the control 
condition and Ccr-treated condition respectively. Error bars represent mean ± SD of four 
technical replicates.
(K) Mitochondrial Oxygen Consumption Rate (OCR) of human UCSD-AML1 and TF-1 
cells treated with 5 mM cyclocreatine (Ccr) in combination with 1 mM phospho-creatine (P-
Cr) for 12 hours prior to measurement under basal conditions, following sequential 
injections of 1 μM ATP synthase inhibitor oligomycin, 1 μM of the uncoupling agent FCCP, 
and 1 μM of the complex I and III inhibitors rotenone and antimycin A, respectively. * p 
value ≤ 0.05 calculated using a Mann-Whitney test in comparison with the control condition. 
Error bars represent mean ± SD of 4 technical replicates.
Each experiment was performed at least two independent times except in G and H in which 
two different EVI1-positive human cell lines transduced with two different CKMT1-directed 
shRNAs were profiled using metabolomics.
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Figure 5. Inhibition of the creatine kinase pathway alters the viability of EVI-1-positive AML 
cells via cell cycle blockade and apoptosis induction
(A) Heatmap of the top common up- and down-regulated genes in human TF-1, UT-7, and 
UCSD-AML1 cell lines treated with cyclocreatine for 24 hours. p value ≤ 0.05, FDR ≤ 0.05, 
and absolute fold change for log2 (FPKM) scores ≥ 1.5. Each column for each condition 
represents an independent biological replicate (n=3 per condition in three individual human 
EVI1-positive cell lines).
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(B–C) A cyclocreatine signature identified by RNAseq was interrogated by GSEA across the 
MsigDB and DMAP database for vehicle versus cyclocreatine-treated AML cells. (B) Top 
enriched upregulated (in red) and downregulated (in blue) gene sets upon cyclocreatine 
treatment are depicted in a functional network. (C) Quantitative comparison of these gene 
sets of interest (in blue or red) versus all other available gene sets (in gray). Data are 
presented as a volcano plot of -log10 (p value) versus Normalized Enrichment Score (NES) 
for each evaluated gene set.
(D–E) May-Grünwald-Giemsa staining of indicated human AML cell lines treated with 8 
mM cyclocreatine for 9 days (D), or infected with a control (shCT) or a CKMT1-directed 
shRNA (E).
(F) Cell size measurement of indicated human AML cell lines treated with 8 mM 
cyclocreatine for 9 days (top panel) or infected with CKMT1-directed shRNAs (bottom 
panel). * p value ≤ 0.05 calculated using Welch’s t-test in comparison with the control 
condition. Error bars represent mean ± SD of three technical replicates.
(G) Cell cycle analysis at the indicated time points of human EVI1-positive cell lines treated 
with cyclocreatine.
(H) FACS plots showing Annexin V (AV) / propidium iodide (PI) profile of the indicated 
human AML cell lines treated with 8 mM cyclocreatine (Ccr) for 5 days.
(I) FACS analysis of the expression of CD117 cell surface marker in the indicated human 
AML cell lines treated with 8 mM cyclocreatine for 9 days (bottom panel) or infected with 
CKMT1-directed shRNAs (top panel). A representative FACS plot from each cell line is 
shown.
(J) Colony formation assay for 2 to 3 rounds of serial replating from indicated human AML 
cell lines treated with either 3 mM or 10 mM cyclocreatine (Ccr). Results represent the 
average of triplicate assays. * p value ≤ 0.05 calculated using a Welch’s t-test in comparison 
to the control condition. Error bars represent mean ± SEM.
Each experiment in D–J was performed at least two independent times.
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Figure 6. CKMT1 knockdown preferentially impairs development of EVI1-positive human and 
murine myeloid leukemias, without affecting normal progenitor cell viability
(A) Western immunoblot for Evi1/EVI1, Ckmt1/CKMT1, and Gapdh/GAPDH (loading 
control) in murine bone marrow cells from wild-type (WT), N-RasG12D, or N-RasG12D + 
Evi1 mouse. Human UCSD-AML1 cell line is used as positive control for EVI1 and 
CKMT1 expression.
(B) Immunoblot indicating the level of Ckmt1 knockdown in murine RFP-sorted bone 
marrow cells seven days post-doxycycline induction.
(C) Kaplan-Meier curves showing overall survival of mice (n = 5 for each group except for 
N-RasG12D + Evi1 shCT + dox group, for which n = 6) transplanted with cells expressing 
each combination of indicated constructs. Statistical significance determined by log-rank 
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(Mantel-Cox) test. * p value ≤ 0.05 by comparison with shControl (shCT) within the N-
RasG12D or the N-RasG12D + Evi1 group.
(D) Spleen weight and white blood cell (WBC) count of four mice per group when 
shControl mice became moribund. P value calculated using a Mann-Whitney test. Error bars 
represent mean ± SEM.
(E) Proportion of Mac-1+ / Gr-1+ cells in spleens from four mice per group. p value 
calculated using a Mann-Whitney test. Error bars represent mean ± SEM.
(F) Proportion of CMP (CD16/32−/CD34+), GMP (CD16/32+/CD34+), and MEP 
(CD16/32−/CD34−) cell populations on gated LinLow/Sca-1−/c-Kit+ myeloid progenitors 
when shControl became moribund. RFP and Venus expression were evaluated on every 
leukemic cell population. One representative moribund mouse from each group is shown.
(G–H) Low U937-Luc (G) and high TF-1 CSF2+-Luc (H) EVI1-expressing human cell lines 
were either infected with two doxycycline-inducible CKMT1-directed miR30-shRNAs (top 
panel) before tail vein injection, or treated with 1g/kg/day cyclocreatine (Ccr) 10 days post-
injection (bottom panel). TF-1-Luc cells were engineered to overexpress CSF2 for efficient 
engraftment in mice. Bioluminescence was quantified weekly as a measure of disease 
burden. Arrows indicates beginning of doxycycline (Dox) or cyclocreatine (Ccr) treatments. 
Data are represented as mean ± SEM of 5 mice per cohort. p value was calculated on the 
latest time point using nonparametric Mann-Whitney test. Kaplan-Meier curves showing 
overall survival of each group of mice is shown in the right panel. Statistical significance 
determined by log-rank (Mantel-Cox) test. n.s, not significant.
(I) Low U937-Luc (top panel) and high TF-1 CSF2+-Luc (bottom panel) EVI1-expressing 
human cell lines were treated with 1g/kg/day cyclocreatine (Ccr) in combination with 
phospho-creatine (P-Cr) at the indicated time point. Bioluminescence was quantified weekly 
as a measure of disease burden. Data are represented as mean ± SEM of seven mice per 
cohort. p value was calculated on the latest time point using a nonparametric Kruskall-Wallis 
test and Dunn’s multiple comparisons test. Kaplan-Meier curves showing overall survival 
(right panel). Statistical significance determined by log-rank (Mantel-Cox) test. * and # p 
value ≤ 0.05 by comparison with vehicle- and Ccr-treated groups respectively. n.s, not 
significant.
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